Bharat Biotech’s COVID-19 vaccine ‘Covaxin’ has received approval for Emergency use in children between 12 to 18 years of age. In a statement, Bharat Biotech said, Covaxin is formulated uniquely such that the same dosage can be administered to adults and children.

It said, Covaxin has established a proven record for safety and efficacy in adults for the original variant and subsequent variants.

The company said it has documented excellent safety and immunogenicity data readouts in children. The company said it looks forward for Covaxin to provide for similar levels of protections for adults and children alike.

It thanked the Health Ministry, NITI Aayog, Drug Controller General of India and India’s National Technical Advisory Group on Immunisation-NTAGI for their diligent review of all data and for their fastidious approval process.


The Indian Awaaz ( is a fast growing English news website based in New Delhi. Website covers Politics, Economy/Business, Entertainment, Health, Education, Technology, Fashion, Lifestyle, Stock Market, Commercial issues and much more. It has separate sections in Hindi and Urdu too.